Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 11/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.48 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | CPB1 | P15086 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30407782 | 0.94 | SIRT2 (0.49) | SIRT2SIRT1SIRT3SIRT5PSMB5 | |
| SCHEMBL30407331 | 0.91 | SIRT2 (0.49) | SIRT2SIRT1SIRT3SIRT5PSMB5 | |
| SCHEMBL25333001 | 0.89 | SIRT2 (0.58) | SIRT2SIRT1SIRT3CPB1CPB2 | |
| SCHEMBL25332996 | 0.89 | SIRT2 (0.58) | SIRT2SIRT1SIRT3CPB1CPB2 | |
| SCHEMBL23451316 | 0.89 | SIRT2 (0.58) | SIRT2SIRT1SIRT3CPB1CPB2 | |
| SCHEMBL23451317 | 0.89 | SIRT2 (0.58) | SIRT2SIRT1SIRT3CPB1CPB2 | |
| SCHEMBL30407623 | 0.88 | SIRT2 (0.46) | SIRT2SIRT1SIRT3SIRT5PSMB5 | |
| SCHEMBL25932961 | 0.88 | SIRT2 (0.59) | SIRT2SIRT1SIRT3SIRT5CPB1 | |
| SCHEMBL30410318 | 0.86 | SIRT2 (0.46) | SIRT2SIRT1SIRT3HDAC4HDAC1 | |
| SCHEMBL30407457 | 0.86 | SIRT2 (0.50) | SIRT2SIRT1SIRT3SIRT5HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | FCGR2A, FCGR3B, FCGR1A | SIRT2 2459/4885SIRT1 3272/4885SIRT3 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.